Study Evaluating Efficacy and Safety of Two Low-dose Regimens of PREMARIN Vaginal Cream for the Treatment of Moderate to Severe Vaginal Atrophy Now...( COLLEGEVILLE Pa. Ju...),Health

COLLEGEVILLE, Pa., July 13 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced the publication of data that supported daily and twice-weekly use of PREMARIN((R)) (conjugated estrogens) Vaginal Cream 0.5 g to relieve some of the bothersome symptoms of moderate-to-severe vulvar and vaginal atrophy, including painful intercourse (dyspareunia). This study evaluated the efficacy of two low-dose regimens of conjugated estrogens (CE) cream (0.5 g daily and twice weekly) using a double-blind, placebo-controlled study design for 12 weeks followed by a 40-week open-label phase. Endometrial safety for both dosing regimens was also assessed in women who completed 52 weeks of therapy. These study results are published in the July/August issue of Menopause: The Journal of the North American Menopause Society.

In this study, dyspareunia was the most bothersome symptom at baseline (57%) followed by vaginal dryness, itching and burning.()Unlike hot flashes or night sweats, signs and symptoms of vaginal atrophy have been shown to increase over time in postmenopausal women.

"Based on market research data, we understand that many postmenopausal women are not discussing their symptoms with their health care professionals," says Gloria Bachmann, M.D., lead study author and director of the Women's Health Institute at the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, N.J., and chief of the OB/GYN service at the teaching hospital. "We are encouraged by this 52-week data that showed twice-weekly use of PREMARIN Vaginal Cream was sufficient to provide relief from painful intercourse due to menopause. The study also supported daily use of PREMARIN Vaginal Cream 0.5 g to treat postmenopausal vaginal dryness. This in
'/>"/>